Clinical related factors to neuroendocrine tumors in Ecuadorian patients: a logistic biplot approach.
Factores clínicos asociados a tumores neuroendocrinos en pacientes ecuatorianos: un análisis biplot logístico.
Palabras clave:
tumores neuroendocrinos, síntomas de cáncer, método estadístico, biplot logístico
Resumen
Los tumores neuroendocrinos (TNE) son relativamente raros y afectan a las células neuroendocrinas de todo el cuerpo. La mayoría de los tumores se diagnostican en etapas avanzadas. La prevalencia de los TNE ha aumentado en los últimos años, pero hay pocos datos en los países en desarrollo. El objetivo de este estudio fue determinar los síntomas asociados a los TNE en pacientes de la Sociedad de Lucha contra el Cáncer (SOLCA) en Ecuador entre 2005 y 2020, utilizando biplots logísticos en una base de datos hospitalaria, generando respuestas binarias (presencia / ausencia) relevantes para este estudio. Los resultados mostraron que la edad promedio era de 59 años y el estudio no encontró diferencias en la prevalencia entre géneros. Los TNE se encontraron con mayor frecuencia en los pulmones (19%), seguidos del estómago (18%) y piel (9%). La mayoría de los pacientes tenían diagnóstico patológico G2 y G3 (30% y 70% respectivamente). Los síntomas como tos, disnea, pérdida de peso, diarrea, estreñimiento, dolor abdominal, dispepsia, crisis hipertensiva, abdomen distendido y obstrucción intestinal tuvieron valores de p <0,05. Además, el análisis estadístico mostró que la tos y la obstrucción intestinal también eran comunes, teniendo en cuenta que los pacientes tenían TNE más frecuentes en los pulmones y la piel. En resumen, nuestros resultados indican que los síntomas de los pacientes con TNE se asociaron positivamente con los pulmones y la piel. Se necesitan más investigaciones que se centren en el tipo de TNE y sus síntomas a fin de establecer un marcador más temprano para el diagnóstico.
Descargas
La descarga de datos todavía no está disponible.
Citas
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 2010; 39(6):707-12. doi: 10.1097/ MPA.0b013e3181ec124e.
Zandee WT, de Herder WW. The evolution of neuroendocrine tumor treatment reflected by ENETS Guidelines. Neuroendocrinol 2018;106(4):357-365. doi: 10.1159/000486096.
Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16(10):590-607. doi: 10.1038/s41574-020-0391-3.
Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Oh-gaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31(12):1770-1786. doi:10.1038/s41379-018-0110-y.
Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutumi H, Fujiyoshi T, Sato T, Hieda N, Yoshida T, Okuno N, Shimizu Y, Yatabe Y, Niwa Y, Yamao K. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol 2015;50(5):564-72. doi: 10.1007/s00535-014-0987-2.
Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen CP, Inzani F, Jann H, Komminoth P, Knigge UP, Landoni L, La Rosa S, Lawlor RT, Luong TV, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt A, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee WT, Zerbi A, Falconi M. Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a Large International Cohort Study. Neuroendocrinol 2018;107(4):375-386. doi: 10.1159/000494355.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26(18):3063-72. doi:10.1200/ JCO.2007.15.4377.
Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tmors and carcinomas. Neoplasia 2017;19(12):991-1002. doi: 10.1016/j. neo.2017.09.002.
Chauhan A, Kohn E, Del Rivero J. Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in Incidence. JAMA Oncol 2020;6(1):21-22. doi: 10.1001/jamaoncol.2019.4568.
Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer 2016;24(9):3695-703. doi:10.1007/ s00520-016-3189-z.
Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 999;340(11):858-68. doi:10.1056/NEJM199903183401107.
Corral Cordero F, Cueva Ayala P, Yépez Maldonado J, Tarupi Montenegro W. Trends in cancer incidence and mortality over three decades in Quito - Ecuador. Colomb Med 2018;49(1):35-41. doi: 10.25100/cm.v49i1.3785.
Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451(4):757-62. doi:10.1007/s00428-007-0452-1.
Vicente-Villardón JL, Galindo-Villardón MP, Blázquez-Zaballos A. Logistic biplots. Multiple correspondence analysis and related methods. London: Chapman & Hall. 2006;503–21.
Gabriel KR. The biplot graphic display of matrices with application to principal component analysis. Biometrika 1971; 58(3), 453-467. doi.org/10.1093/biomet/58.3.453.
Sharov AA, Dudekula DB, Ko MSH. A web- based tool for principal component and significance analysis of microarray data. Bioinformatics 2005; 21(10), 2548-2549 doi:10.1093/bioinformatics/bti343.
Bravata DM, Shojania KG, Olkin I, Raveh A. CoPlot: a tool for visualizing multivariate data in medicine. Stat Med 2008;27(12):2234-47. doi1 0.1002/sim.3078.
Sepúlveda R, Vicente-Villardón JL, Galindo MP. The Biplot as a diagnostic tool of local dependence in latent class models. A medical application. Stat Med 2008;27(11):1855-69. doi: 10.1002/sim.3194.
Demey JR, Vicente-Villardón JL, Galindo-Villardón MP, Zambrano AY. Identifying molecular markers associated with classification of genotypes by External Logistic Bi-plots. Bioinformatics 2008; 24(24), 2832-2838. doi:10.1093/bioinformatics/btn552.
Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu FL, Yang HM, et al. The international HapMap project. 2003. doi:10.1038/ nature02168.
Gallego-Alvarez I, Ortas E, Vicente-Villardón JL, Álvarez Etxeberria I. Institutional constraints, stakeholder pressure and corporate environmental reporting policies. Bus Strateg Environ 2017; 26(6), 807-825. doi.org/10.1002/bse.1952.
Cañueto J, Cardeñoso-Álvarez E, García- Hernández JL, Galindo-Villardón P, Vicente- Galindo P, Vicente-Villardón JL, Alonso-López D, De Las Rivas J, Valero J, Moyano-Sanz E, Fernández-López E, Mao JH, Castellanos- Martín A, Román-Curto C, Pérez-Losada J. MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma. Br J Der- matol 2017;177(1):168-178. doi: 10.1111/ bjd. 15236.
Hernández-Sánchez JC, Vicente-Villardón JL. Logistic biplot for nominal data. Adv Data Anal Classif 11. 2017; 11(2), 307-326. doi.org/10.1007/s11634-016-0249-7.
Vicente-Villardón, J.L. MULTBIPLOT: A package for Multivariate Analysis using Bi-plots. Departamento de Estadística. Universidad de Salmanca. 2010. (http://biplot. usal.es/ClassicalBiplot/index.html).
Vicente-Villardón, J.L. MultBiplotR: Multivariate Analysis using Biplots. R package version 0.1. 0. Website http://biplot.usal.es/multbiplot/multbiplot–in–r/[accessed 20 November 2019].
Chen TY, Morrison AO, Susa J, Cockerell CJ. Primary low-grade neuroendocrine carcinoma of the skin: An exceedingly rare entity. J Cutan Pathol 2017;44(11):978-81. doi: 10.1111/cup.13028.
Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139(12):2679-2686. doi:10.1002/ijc.30400.
Chapman S, Schenk P, Kazan K, Manners, Using biplots to interpret gene expression patterns in plants. Bioinformatics 2002; 18(1), 202-204. doi.org/10.1093/bioinformatics/18.1.202.
Gabriel, K. R. Generalised bilinear regression. Biometrika 1998; 85(3), 689-700. doi. org/10.1093/biomet/85.3.689
Gabriel KR, Zamir S. Lower rank approximation of matrices by least squares with any choice of weights. Technometrics 1979; 21 : 489-498.
Gower JC, Hand DJ. Biplots 1995; 54. CRC Press. Jongman, E, & Jongman, S R R Data analysis in community and landscape ecology. Cambridge University Press, 1995.
Vanoli A, Albarello L, Uncini S, Fassan M, Grillo F, Di Sabatino A, Martino M, Pasquali C, Milanetto AC, Falconi M, Partelli S, Doglioni C, Schiavo-Lena M, Brambilla T, Pietrabissa A, Sessa F, Capella C, Rindi G, La Rosa S, Solcia E, Paulli M. Neuroendocrine tumors (NETs) of the minor papilla/ampulla: analysis of 16 cases underlines homology with major ampulla NETs and differences from extra-ampullary duodenal NETs. Am J Surg Pathol 2019;43(6):725- 736. doi:10.1097/PAS.0000000000001234.
Lloyd R V, Osamura YR, Kloppel G, Rosai WHO classification of tumours of endocrine organs. WHO Press 2017; WHO Classification of Tumours, 4th Edition, Volume 10.
Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinol 2004;80 (Suppl 1):3-7. doi: 10.1159/000080731.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3(10):1335-1342. doi: 10.1001/ja-maoncol. 2017.0589.
Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH, Chang H, Jung ES, Kim HK, Jin SY, Choi JH, Gu MJ, Kim S, Kang MS, Cho CH, Park MI, Kang YK, Kim YW, Yoon SO, Bae HI, Joo M, Moon WS, Kang DY, Chang SJ. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000- 2009: Multicenter Study. Cancer Res Treat 2012;44(3):157-165. doi: 10.4143/ crt.2012.44.3.157.
Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 2018;9(27):19245-19254. doi: 10.18632/oncotarget.24983.
Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89(3):151- 160. doi: 10.1002/jso.20179.
Rupp AB, Ahmadjee A, Morshedzadeh JH, Ranjan R. Carcinoid syndrome- induced ventricular tachycardia. Case Rep Cardiol 2016;2016:9142598. doi: 10.1155/2016/9142598.
McCormick D. Carcinoid tumors and syndrome. Gastroenterol Nurs 2002;25(3):105- 11. doi: 10.1097/00001610-200205000-00004.
Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC. North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 2010;39(6):753-766. doi:10.1097/ MPA.0b013e3181ebb2a5.
Toth-Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg 2004;187(5):575- 579. doi: 10.1016/j.amjsurg.2004.01.019.
Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 2012;41(3):461-466. doi: 10.1097/ MPA.0b013e3182328045.
Jedrych J, Pulitzer M. Primary carcinoid tumor of the skin: a literature review. Int J Surg Pathol 2014;22(2):129-135. doi: 10.1177/1066896913516672.
Terada T. Primary cutaneous neuroendocrine tumor (atypical carcinoid) expressing KIT and PDGFRA with myoepithelial differentiation: a case report with immunohistochemical and molecular genetic studies. Int J Clin Exp Pathol 2013;6(4):802-809.
Koo HS, Sohn YM, Park YK. Sonographic appearance of a neuroendocrine tumor arising in the axilla: case report and literature review. J Clin Ultrasound 2014;42(1):30- 32. doi: 10.1002/jcu.22024.
Santos-Juanes J, Fernández-Vega I, Fuentes N, Galache C, Coto-Segura P, Vivanco B, Astudillo A, Martínez-Camblor P. Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta-analysis. Br J Dermatol 2015;173(1):42-49. doi: 10.1111/bjd.13870.
Daoud MA, Mete O, Al Habeeb A, Ghazarian D. Neuroendocrine carcinoma of the skin--an updated review. Semin Diagn Pathol 2013;30(3):234-244. doi:10.1053/j. semdp.2013.07.002.
Goto K, Anan T, Fukumoto T, Kimura T, Misago N. Carcinoid-like/labyrinthine pattern in sebaceous neoplasms represents a sebaceous mantle phenotype: immuno-histochemical analysis of aberrant vimentin expression and cytokeratin 20-positive Merkel cell distribution. Am J Dermatopathol 2017;39(11):803-810. doi:10.1097/ DAD.0000000000000806.
Leventhal JS, Braverman IM. Skin manifestations of endocrine and neuroendocrine tumors. Semin Oncol 2016;43(3):335-340. doi: 10.1053/j.seminoncol.2016.02.022.
Zandee WT, de Herder WW. The evolution of neuroendocrine tumor treatment reflected by ENETS Guidelines. Neuroendocrinol 2018;106(4):357-365. doi: 10.1159/000486096.
Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16(10):590-607. doi: 10.1038/s41574-020-0391-3.
Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Oh-gaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31(12):1770-1786. doi:10.1038/s41379-018-0110-y.
Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutumi H, Fujiyoshi T, Sato T, Hieda N, Yoshida T, Okuno N, Shimizu Y, Yatabe Y, Niwa Y, Yamao K. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol 2015;50(5):564-72. doi: 10.1007/s00535-014-0987-2.
Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen CP, Inzani F, Jann H, Komminoth P, Knigge UP, Landoni L, La Rosa S, Lawlor RT, Luong TV, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt A, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee WT, Zerbi A, Falconi M. Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a Large International Cohort Study. Neuroendocrinol 2018;107(4):375-386. doi: 10.1159/000494355.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26(18):3063-72. doi:10.1200/ JCO.2007.15.4377.
Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tmors and carcinomas. Neoplasia 2017;19(12):991-1002. doi: 10.1016/j. neo.2017.09.002.
Chauhan A, Kohn E, Del Rivero J. Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in Incidence. JAMA Oncol 2020;6(1):21-22. doi: 10.1001/jamaoncol.2019.4568.
Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer 2016;24(9):3695-703. doi:10.1007/ s00520-016-3189-z.
Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 999;340(11):858-68. doi:10.1056/NEJM199903183401107.
Corral Cordero F, Cueva Ayala P, Yépez Maldonado J, Tarupi Montenegro W. Trends in cancer incidence and mortality over three decades in Quito - Ecuador. Colomb Med 2018;49(1):35-41. doi: 10.25100/cm.v49i1.3785.
Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451(4):757-62. doi:10.1007/s00428-007-0452-1.
Vicente-Villardón JL, Galindo-Villardón MP, Blázquez-Zaballos A. Logistic biplots. Multiple correspondence analysis and related methods. London: Chapman & Hall. 2006;503–21.
Gabriel KR. The biplot graphic display of matrices with application to principal component analysis. Biometrika 1971; 58(3), 453-467. doi.org/10.1093/biomet/58.3.453.
Sharov AA, Dudekula DB, Ko MSH. A web- based tool for principal component and significance analysis of microarray data. Bioinformatics 2005; 21(10), 2548-2549 doi:10.1093/bioinformatics/bti343.
Bravata DM, Shojania KG, Olkin I, Raveh A. CoPlot: a tool for visualizing multivariate data in medicine. Stat Med 2008;27(12):2234-47. doi1 0.1002/sim.3078.
Sepúlveda R, Vicente-Villardón JL, Galindo MP. The Biplot as a diagnostic tool of local dependence in latent class models. A medical application. Stat Med 2008;27(11):1855-69. doi: 10.1002/sim.3194.
Demey JR, Vicente-Villardón JL, Galindo-Villardón MP, Zambrano AY. Identifying molecular markers associated with classification of genotypes by External Logistic Bi-plots. Bioinformatics 2008; 24(24), 2832-2838. doi:10.1093/bioinformatics/btn552.
Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu FL, Yang HM, et al. The international HapMap project. 2003. doi:10.1038/ nature02168.
Gallego-Alvarez I, Ortas E, Vicente-Villardón JL, Álvarez Etxeberria I. Institutional constraints, stakeholder pressure and corporate environmental reporting policies. Bus Strateg Environ 2017; 26(6), 807-825. doi.org/10.1002/bse.1952.
Cañueto J, Cardeñoso-Álvarez E, García- Hernández JL, Galindo-Villardón P, Vicente- Galindo P, Vicente-Villardón JL, Alonso-López D, De Las Rivas J, Valero J, Moyano-Sanz E, Fernández-López E, Mao JH, Castellanos- Martín A, Román-Curto C, Pérez-Losada J. MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma. Br J Der- matol 2017;177(1):168-178. doi: 10.1111/ bjd. 15236.
Hernández-Sánchez JC, Vicente-Villardón JL. Logistic biplot for nominal data. Adv Data Anal Classif 11. 2017; 11(2), 307-326. doi.org/10.1007/s11634-016-0249-7.
Vicente-Villardón, J.L. MULTBIPLOT: A package for Multivariate Analysis using Bi-plots. Departamento de Estadística. Universidad de Salmanca. 2010. (http://biplot. usal.es/ClassicalBiplot/index.html).
Vicente-Villardón, J.L. MultBiplotR: Multivariate Analysis using Biplots. R package version 0.1. 0. Website http://biplot.usal.es/multbiplot/multbiplot–in–r/[accessed 20 November 2019].
Chen TY, Morrison AO, Susa J, Cockerell CJ. Primary low-grade neuroendocrine carcinoma of the skin: An exceedingly rare entity. J Cutan Pathol 2017;44(11):978-81. doi: 10.1111/cup.13028.
Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139(12):2679-2686. doi:10.1002/ijc.30400.
Chapman S, Schenk P, Kazan K, Manners, Using biplots to interpret gene expression patterns in plants. Bioinformatics 2002; 18(1), 202-204. doi.org/10.1093/bioinformatics/18.1.202.
Gabriel, K. R. Generalised bilinear regression. Biometrika 1998; 85(3), 689-700. doi. org/10.1093/biomet/85.3.689
Gabriel KR, Zamir S. Lower rank approximation of matrices by least squares with any choice of weights. Technometrics 1979; 21 : 489-498.
Gower JC, Hand DJ. Biplots 1995; 54. CRC Press. Jongman, E, & Jongman, S R R Data analysis in community and landscape ecology. Cambridge University Press, 1995.
Vanoli A, Albarello L, Uncini S, Fassan M, Grillo F, Di Sabatino A, Martino M, Pasquali C, Milanetto AC, Falconi M, Partelli S, Doglioni C, Schiavo-Lena M, Brambilla T, Pietrabissa A, Sessa F, Capella C, Rindi G, La Rosa S, Solcia E, Paulli M. Neuroendocrine tumors (NETs) of the minor papilla/ampulla: analysis of 16 cases underlines homology with major ampulla NETs and differences from extra-ampullary duodenal NETs. Am J Surg Pathol 2019;43(6):725- 736. doi:10.1097/PAS.0000000000001234.
Lloyd R V, Osamura YR, Kloppel G, Rosai WHO classification of tumours of endocrine organs. WHO Press 2017; WHO Classification of Tumours, 4th Edition, Volume 10.
Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinol 2004;80 (Suppl 1):3-7. doi: 10.1159/000080731.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3(10):1335-1342. doi: 10.1001/ja-maoncol. 2017.0589.
Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, Kim H, Kook MC, Park DY, Lee JH, Chang H, Jung ES, Kim HK, Jin SY, Choi JH, Gu MJ, Kim S, Kang MS, Cho CH, Park MI, Kang YK, Kim YW, Yoon SO, Bae HI, Joo M, Moon WS, Kang DY, Chang SJ. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000- 2009: Multicenter Study. Cancer Res Treat 2012;44(3):157-165. doi: 10.4143/ crt.2012.44.3.157.
Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 2018;9(27):19245-19254. doi: 10.18632/oncotarget.24983.
Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89(3):151- 160. doi: 10.1002/jso.20179.
Rupp AB, Ahmadjee A, Morshedzadeh JH, Ranjan R. Carcinoid syndrome- induced ventricular tachycardia. Case Rep Cardiol 2016;2016:9142598. doi: 10.1155/2016/9142598.
McCormick D. Carcinoid tumors and syndrome. Gastroenterol Nurs 2002;25(3):105- 11. doi: 10.1097/00001610-200205000-00004.
Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC. North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 2010;39(6):753-766. doi:10.1097/ MPA.0b013e3181ebb2a5.
Toth-Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg 2004;187(5):575- 579. doi: 10.1016/j.amjsurg.2004.01.019.
Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 2012;41(3):461-466. doi: 10.1097/ MPA.0b013e3182328045.
Jedrych J, Pulitzer M. Primary carcinoid tumor of the skin: a literature review. Int J Surg Pathol 2014;22(2):129-135. doi: 10.1177/1066896913516672.
Terada T. Primary cutaneous neuroendocrine tumor (atypical carcinoid) expressing KIT and PDGFRA with myoepithelial differentiation: a case report with immunohistochemical and molecular genetic studies. Int J Clin Exp Pathol 2013;6(4):802-809.
Koo HS, Sohn YM, Park YK. Sonographic appearance of a neuroendocrine tumor arising in the axilla: case report and literature review. J Clin Ultrasound 2014;42(1):30- 32. doi: 10.1002/jcu.22024.
Santos-Juanes J, Fernández-Vega I, Fuentes N, Galache C, Coto-Segura P, Vivanco B, Astudillo A, Martínez-Camblor P. Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta-analysis. Br J Dermatol 2015;173(1):42-49. doi: 10.1111/bjd.13870.
Daoud MA, Mete O, Al Habeeb A, Ghazarian D. Neuroendocrine carcinoma of the skin--an updated review. Semin Diagn Pathol 2013;30(3):234-244. doi:10.1053/j. semdp.2013.07.002.
Goto K, Anan T, Fukumoto T, Kimura T, Misago N. Carcinoid-like/labyrinthine pattern in sebaceous neoplasms represents a sebaceous mantle phenotype: immuno-histochemical analysis of aberrant vimentin expression and cytokeratin 20-positive Merkel cell distribution. Am J Dermatopathol 2017;39(11):803-810. doi:10.1097/ DAD.0000000000000806.
Leventhal JS, Braverman IM. Skin manifestations of endocrine and neuroendocrine tumors. Semin Oncol 2016;43(3):335-340. doi: 10.1053/j.seminoncol.2016.02.022.
Publicado
2022-03-21
Cómo citar
Montes Escobar, K., Vicente Villardón, J. L., Alarcón Cano, D. F., & Siteneski, A. (2022). Clinical related factors to neuroendocrine tumors in Ecuadorian patients: a logistic biplot approach.: Factores clínicos asociados a tumores neuroendocrinos en pacientes ecuatorianos: un análisis biplot logístico. Investigación Clínica, 63(1), 19-31. https://doi.org/10.54817/IC.v63n1a02
Sección
Trabajos Originales
